Frank Reed

Unpacking the breakthroughs that are redefining the limits of human potential.

FR

Editor

Frank Reed

About This Column

Frank Reed is a strategist and analyst who explores the frontiers of what is possible. Formerly the expert voice behind Precision Future, Frank has expanded his scope to examine the groundbreaking advancements reshaping the human experience. From the ethics of gene editing to the transformative power of artificial intelligence, he specializes in deconstructing the science behind the headlines. His column offers a nuanced understanding of the forces driving the next era of innovation, providing readers with a clear and compelling vision of how technology will revolutionize our world.

Displaying items 641-660 of 708 in total

Frank Reed 7 months ago

Balyasny's Derivative Play in Just Group's £2.4B Takeover

Hedge fund Balyasny reveals a 1.26% economic stake in Just Group via derivatives, shining a light on the complex strategies at play in its takeover.

Read full article

Frank Reed 7 months ago

Weiss Asset Management Ups Avadel Stake Amid High-Stakes Takeover Battle

A regulatory filing reveals a key investor's move as Alkermes' $2.1B bid for Avadel and its blockbuster narcolepsy drug, LUMRYZ, nears its final act.

Read full article

Frank Reed 7 months ago

Qualcomm's AI Gambit: Inside the High-Stakes Alphawave Takeover

A $2.4B deal for AI's future. A hedge fund's strategic play. We decode the battle for Alphawave, the company powering the next tech revolution.

Read full article

Frank Reed 7 months ago

Qualcomm's Chip Deal: The Hidden Engine of Future Health Tech

A $2.4B semiconductor deal seems distant from medicine, but it's forging the AI hardware backbone for the next generation of precision health.

Read full article

Frank Reed 7 months ago

Hedge Fund Moves Signal Endgame in Avadel Pharma Takeover Battle

Regulatory filings reveal Balyasny Asset Management's strategic trades in Avadel Pharma, offering a glimpse into the high-stakes bidding war with Alkermes.

Read full article

Frank Reed 7 months ago

Hedge Fund's £2.3bn Derivatives Play in JTC Takeover Decoded

Balyasny Asset Management's complex derivative stake in JTC plc reveals the hidden strategies shaping a major takeover and the capital flows funding innovation.

Read full article

Frank Reed 7 months ago

Balyasny Trims Just Group Stake, Shining Light on UK Takeover Rules

A mandatory filing reveals hedge fund Balyasny's 1.26% CFD stake in Just Group, offering a rare glimpse into high-stakes M&A strategy and regulation.

Read full article

Frank Reed 7 months ago

Hedge Fund Moves Signal High-Stakes Battle for Avadel Pharmaceuticals

A regulatory filing from Balyasny Asset Management reveals intense investor activity as a bidding war for narcolepsy drugmaker Avadel heats up.

Read full article

Frank Reed 7 months ago

Hedge Fund's Dual Bet Reveals High-Stakes Battle for AI's Foundation

A regulatory filing from Weiss Asset Management reveals a complex arbitrage play on Alphawave IP, spotlighting its critical role in the Qualcomm deal.

Read full article

Frank Reed 7 months ago

Decoding Qualcomm's AI Deal: The Silicon Fueling Health Tech's Future

A $2.4B tech acquisition seems distant from healthcare, but Qualcomm's move to buy Alphawave is building the essential AI infrastructure for medicine's future.

Read full article

Frank Reed 7 months ago

Weiss Asset Management Ups Avadel Stake Amid $2.37B Acquisition

A strategic investment firm's move signals strong confidence in the closing of Avadel's multi-billion dollar deal, spotlighting its blockbuster sleep drug.

Read full article

Frank Reed 7 months ago

Balyasny's Derivative Play in Just Group Signals Arbitrage Strategy

A 1.26% stake in Just Group, held via derivatives by Balyasny, reveals a classic merger arbitrage strategy as Brookfield's £2.4bn acquisition nears.

Read full article

Frank Reed 7 months ago

Sintana's Strategic Gambit: More Than Just a Share Count Update

A routine regulatory filing reveals Sintana Energy's major M&A play. We decode the signals, the Challenger deal, and what it means for its oil future.

Read full article

Sintana's Strategic Gambit: More Than Just a Share Count Update

Frank Reed 7 months ago

Rathbones' Stake Highlights Idox's Pivotal Take-Private Journey

A routine filing from wealth manager Rathbones reveals its 7.01% stake in Idox Plc, putting a spotlight on the software firm's acquisition and its future.

Read full article

Frank Reed 8 months ago

UK Student Housing Heats Up: Balyasny's Play in the Unite-Empiric Deal

Hedge fund Balyasny Asset Management reveals a major stake in the Unite-Empiric takeover, signaling a high-stakes arbitrage play amid regulatory scrutiny.

Read full article

Frank Reed 8 months ago

Hedge Fund’s Spectris Play Reveals the Real Money in Health Tech

A last-minute regulatory filing by Balyasny Asset Management pulls back the curtain on the multi-billion-dollar battle for Spectris, a key health tech enabler.

Read full article

Frank Reed 8 months ago

Balyasny’s Avadel Stake Reveals Endgame in Pharma Bidding War

A regulatory filing shows hedge fund Balyasny's active trading in Avadel Pharma, exposing a merger arbitrage strategy amid a fierce bidding war.

Read full article

Frank Reed 8 months ago

Qualcomm's Quiet Move: What a Filing Reveals About AI's Future in Medicine

A routine financial disclosure from an asset manager unveils Qualcomm's $2.4B bet on Alphawave, signaling a major push into the AI infrastructure that powers health tech.

Read full article

Frank Reed 8 months ago

Hedge Fund Signals: Balyasny Trims Just Group Stake Amid Takeover

A regulatory filing reveals Balyasny Asset Management's strategic trading in Just Group as the stock hits a 52-week high during a takeover.

Read full article

Frank Reed 8 months ago

Balyasny’s Avadel Stake Reveals High-Stakes M&A Game in Pharma

A routine regulatory filing by hedge fund Balyasny pulls back the curtain on a multi-billion dollar bidding war for Avadel Pharmaceuticals. Here's why.

Read full article

UCID: 16